{"url_path":"/sec/aeon/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000046-index.html","accession_number":"0001837607-26-000046","cik":"0001837607","ticker":"AEON","issuer_name":"AEON Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1837607/0001837607-26-000046-index.html","primary_entity_key":"0001837607","primary_entity_name":"AEON Biopharma, Inc."},"word_count":345,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\nAEON Biopharma, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 17, 2026 (the “Annual Meeting”) as described in the Company’s proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission (the “SEC”) on April 29, 2026 (the “2026 Proxy”). At the Annual Meeting, the stockholders of the Company voted on two proposals as further described in the 2026 Proxy. The final results for each proposal voted on by the stockholders at the Annual Meeting, as certified by the Company’s inspector of elections, are set forth below.\n\nProposal 1: The stockholders of the Company elected each of Marc Forth and Seongsoo Park as Class III directors of the Company’s board of directors (the “Class III Directors”) for a three-year term ending at the Annual Meeting of Stockholders to be held in 2029 and until their respective successors have been duly elected and qualified. The voting results with respect to the election of the Class III Directors were as follows:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Nominee**\n\n​\n\n**Term Expiring**\n\n​\n\n**For**\n\n​\n\n**Withheld**\n\n​\n\n**Broker Non-Vote**\n\nMarc Forth\n\n​\n\n2029\n\n​\n\n13,297,322\n\n​\n\n27,738\n\n​\n\n8,197,073\n\nSeongsoo Park\n\n​\n\n2029\n\n​\n\n13,117,299\n\n​\n\n207,761\n\n​\n\n8,197,073\n\nProposal 2: The stockholders of the Company ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. The voting results for this proposal were as follows:\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**For**\n\n​\n\n**Against**\n\n​\n\n**Abstain**\n\n​\n\n**Broker Non-Vote**\n\n21,502,418\n\n​\n\n18,217\n\n​\n\n1,498\n\n​\n\n—\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nSIGNATURE\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**AEON Biopharma, Inc.**\n\nDate: June 17, 2026\n\nBy:\n\n/s/ Robert Bancroft\n\n​\n\n​\n\nRobert Bancroft\n\n​\n\n​\n\nChief Executive Officer\n\n​\n\n​\n\n​"}